Author:
Ehlken C,Jungmann S,Böhringer D,Agostini H T,Junker B,Pielen A
Publisher
Springer Science and Business Media LLC
Reference18 articles.
1. Velez-Montoya R, Oliver SCN, Olson JL, Fine SL, Mandava N, Quiroz-Mercado H . Current knowledge and trends in age-related macular degeneration: today’s and future treatments. Retina 2012; 33 (8): 1487–1502.
2. Schmidt-Erfurth U, Pollreisz A, Mitsch C, Bolz M . Antivascular Endothelial Growth Factors in Age-Related Macular Degeneration. In: Bandello F, Battaglia Parodi M, Augustin AJ, Iacono P, Schlingemann RO, Schmidt-Erfurth U, (eds). Developments in Ophthalmology. KARGER: Basel, Switzerland, 2010 pp 21–38.
3. Klettner A, Roider J . Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways. Invest Ophthalmol Vis Sci 2008; 49 (10): 4523–4527.
4. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364 (20): 1897–1908.
5. CATT Research Group, Martin DF, Maguire MG, Fine SL, Ying G-S, Jaffe GJ et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012; 119 (7): 1388–1398.
Cited by
81 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献